FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034800789> ?p ?o ?g. }

• W2034800789 endingPage "1352" @default.
• W2034800789 startingPage "1346" @default.
• W2034800789 abstract "BACKGROUND Chemoradiotherapy is widely used for patients with locally advanced pancreatic carcinoma. The purpose of this study was to clarify the efficacy and feasibility of chemoradiotherapy with more intensive radiotherapy in these patients, using a combination of intraoperative radiotherapy (IORT), conformal external-beam radiaotherapy (EBRT), and protracted 5-fluorouracil (5-FU). METHODS Thirty patients with unresectable locally advanced pancreatic carcinoma were enrolled in this Phase II study. The treatment consisted of IORT (25 grays [Gy]), followed by EBRT (40 Gy in 20 fractions, 5 times per week), and concurrent protracted 5-FU infusion (200 mg/m2), beginning 2–4 weeks after IORT. The authors evaluated the efficacy and adverse effects of this treatment by following up patients for 12.0–28.1 months. Survival from the date of IORT was calculated using the Kaplan–Meier method. RESULTS In 11 of the 30 patients, metastatic spread was detected in the abdominal cavity at laparotomy. The full EBRT dose was administered in 28 of the 30 patients. Of the remaining 2 patients, EBRT was terminated at 8 Gy due to progression of brain metastasis and another patient did not receive EBRT or chemotherapy due to massive ascites after IORT. The overall response rate for primary pancreatic tumor on dynamic computed tomography scan was 23.3% (7 partial responses). Grade 3 or 4 toxicity (according to the National Cancer Institute Common Toxicity Criteria) was observed in 15 of the 28 patients who received the full irradiation dose (53.6%). These included anorexia, nausea, emesis, fatigue, leukopenia, and/or elevation of transaminase levels. There were no directly treatment-related deaths, but 1 patient died of hepatic failure related to late effects of irradiation after 25.6 months. The median survival time of the 30 patients was 7.8 months and the 2-year survival rate was 8.1%. The median survival time of the 19 patients without metastatic spread in the abdominal cavity was 12.9 months and that of the 11 patients with metastatic spread was 5.8 months. CONCLUSIONS The present regimen of chemoradiotherapy is not superior to conventional chemoradiotherapy (EBRT and 5-FU) for patients with locally advanced pancreatic carcinoma. Cancer 2003;97:1346–52. © 2003 American Cancer Society. DOI 10.1002/cncr.11165" @default.
• W2034800789 created "2016-06-24" @default.
• W2034800789 creator A5001230513 @default.
• W2034800789 creator A5002423375 @default.
• W2034800789 creator A5004918113 @default.
• W2034800789 creator A5010190969 @default.
• W2034800789 creator A5042079103 @default.
• W2034800789 creator A5056197140 @default.
• W2034800789 creator A5057311746 @default.
• W2034800789 creator A5057460944 @default.
• W2034800789 creator A5068327028 @default.
• W2034800789 creator A5077055208 @default.
• W2034800789 creator A5079977395 @default.
• W2034800789 creator A5085631531 @default.
• W2034800789 date "2003-02-20" @default.
• W2034800789 modified "2023-10-16" @default.
• W2034800789 title "Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma" @default.
• W2034800789 cites W1763850369 @default.
• W2034800789 cites W1894182878 @default.
• W2034800789 cites W1926559864 @default.
• W2034800789 cites W1931508686 @default.
• W2034800789 cites W1954948139 @default.
• W2034800789 cites W1965073087 @default.
• W2034800789 cites W1972373303 @default.
• W2034800789 cites W1987948753 @default.
• W2034800789 cites W1989407605 @default.
• W2034800789 cites W1994461500 @default.
• W2034800789 cites W2000424590 @default.
• W2034800789 cites W2002138142 @default.
• W2034800789 cites W2016236483 @default.
• W2034800789 cites W2024210946 @default.
• W2034800789 cites W2043287087 @default.
• W2034800789 cites W2054823131 @default.
• W2034800789 cites W2065988681 @default.
• W2034800789 cites W2067053040 @default.
• W2034800789 cites W2071379614 @default.
• W2034800789 cites W2080080319 @default.
• W2034800789 cites W2083513265 @default.
• W2034800789 cites W2084562398 @default.
• W2034800789 cites W2106236272 @default.
• W2034800789 cites W2128161510 @default.
• W2034800789 cites W2130660535 @default.
• W2034800789 cites W4231031590 @default.
• W2034800789 cites W4253769310 @default.
• W2034800789 doi "https://doi.org/10.1002/cncr.11165" @default.
• W2034800789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12599244" @default.
• W2034800789 hasPublicationYear "2003" @default.
• W2034800789 type Work @default.
• W2034800789 sameAs 2034800789 @default.
• W2034800789 citedByCount "27" @default.
• W2034800789 countsByYear W20348007892012 @default.
• W2034800789 countsByYear W20348007892013 @default.
• W2034800789 countsByYear W20348007892014 @default.
• W2034800789 countsByYear W20348007892015 @default.
• W2034800789 countsByYear W20348007892020 @default.
• W2034800789 countsByYear W20348007892023 @default.
• W2034800789 crossrefType "journal-article" @default.
• W2034800789 hasAuthorship W2034800789A5001230513 @default.
• W2034800789 hasAuthorship W2034800789A5002423375 @default.
• W2034800789 hasAuthorship W2034800789A5004918113 @default.
• W2034800789 hasAuthorship W2034800789A5010190969 @default.
• W2034800789 hasAuthorship W2034800789A5042079103 @default.
• W2034800789 hasAuthorship W2034800789A5056197140 @default.
• W2034800789 hasAuthorship W2034800789A5057311746 @default.
• W2034800789 hasAuthorship W2034800789A5057460944 @default.
• W2034800789 hasAuthorship W2034800789A5068327028 @default.
• W2034800789 hasAuthorship W2034800789A5077055208 @default.
• W2034800789 hasAuthorship W2034800789A5079977395 @default.
• W2034800789 hasAuthorship W2034800789A5085631531 @default.
• W2034800789 hasBestOaLocation W20348007891 @default.
• W2034800789 hasConcept C121608353 @default.
• W2034800789 hasConcept C126322002 @default.
• W2034800789 hasConcept C126838900 @default.
• W2034800789 hasConcept C141071460 @default.
• W2034800789 hasConcept C2775908122 @default.
• W2034800789 hasConcept C2776694085 @default.
• W2034800789 hasConcept C2777416452 @default.
• W2034800789 hasConcept C2778424827 @default.
• W2034800789 hasConcept C2780210213 @default.
• W2034800789 hasConcept C2780580376 @default.
• W2034800789 hasConcept C2780873365 @default.
• W2034800789 hasConcept C509974204 @default.
• W2034800789 hasConcept C71924100 @default.
• W2034800789 hasConceptScore W2034800789C121608353 @default.
• W2034800789 hasConceptScore W2034800789C126322002 @default.
• W2034800789 hasConceptScore W2034800789C126838900 @default.
• W2034800789 hasConceptScore W2034800789C141071460 @default.
• W2034800789 hasConceptScore W2034800789C2775908122 @default.
• W2034800789 hasConceptScore W2034800789C2776694085 @default.
• W2034800789 hasConceptScore W2034800789C2777416452 @default.
• W2034800789 hasConceptScore W2034800789C2778424827 @default.
• W2034800789 hasConceptScore W2034800789C2780210213 @default.
• W2034800789 hasConceptScore W2034800789C2780580376 @default.
• W2034800789 hasConceptScore W2034800789C2780873365 @default.
• W2034800789 hasConceptScore W2034800789C509974204 @default.
• W2034800789 hasConceptScore W2034800789C71924100 @default.
• W2034800789 hasIssue "5" @default.
• W2034800789 hasLocation W20348007891 @default.

• next